-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse NasdaqUSDISIN CH0334081137-
CRISPR TherapeuticsBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol 1CG
-
CRISPR TherapeuticsBörse Börse BerlinEURSymbol 1CG
-
CRISPR TherapeuticsBörse Börse StuttgartEURSymbol 1CG
-
CRISPR TherapeuticsBörse Börse DüsseldorfEURSymbol 1CG
-
CRISPR TherapeuticsBörse Börse MünchenEURSymbol 1CG
-
CRISPR TherapeuticsBörse Börse FrankfurtEURSymbol 1CG
-
CRISPR TherapeuticsBörse Gettex System der Börse MünchenEURSymbol 1CG
-
CRISPR TherapeuticsBörse NasdaqISIN CH0334081137 WKN: A2AT0ZUSDSymbol CRSP
-
ISIN CH0334081137 WKN: A2AT0ZUSDSymbol CRSP
-
MXN
-
USD
-
ISIN CH0334081137
WKN A2AT0Z
Symbol CRSP
Währung
USD
Börse
Nasdaq Zeitzone: Europe/London
Firmenname
CRISPR Therapeutics AG
Marktkapitalisierung
8.806.828.960 (+- 8%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
9.480.657.920 oder 8.133.000.000
Mitarbeiter
434 (+- 6%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
410 oder 458 Mitarbeiter
KGV
124.34
EBITDA 2.869.000
Buchwert 22.516
CRISPR Therapeutics outperformed den DAX um +755 % vom 19.10.2016 bis 18.06.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 129,69 USD +0,37%
Portrait der CRISPR Therapeutics Aktie
Das Unternehmen CRISPR Therapeutics AG aus USA beschäftigt 434 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Gesundheitsdienstleistungen tätig.
Die CRISPR Therapeutics Aktie konnte seit dem 19.10.2016 eine Rendite von sage und schreibe 803% erwirtschaften.
Das Unternehmen CRISPR Therapeutics AG ist in ungefähr 13 ETFs enthalten und somit eine nicht sonderlich bekannte oder beliebte Aktie. Der Spitzenreiter Global X Genomics & Biotechnology ETF gewichtet CRISPR Therapeutics mit 3,84% im ETF.
Entdecke die 6 ETFs in denen CRISPR Therapeutics AG am höchsten gewichtet ist Insgesamt in 13 ETFs enthalten
Dir gefallen die Informationen zu CRISPR Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu CRISPR Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu CRISPR Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu CRISPR Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
83 News & Informationen zur CRISPR Therapeutics Aktie
What’s Next For CRISPR Stock After An 11% Fall In A Week?
The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a sell-off drove the stock price down over 40% to its current level of around $119…
What’s Next For CRISPR Stock After An 11% Fall In A Week?
The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a sell-off drove the stock price down over 40% to its current level of around $119…
What’s Next For CRISPR Stock After An 11% Fall In A Week?
The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a sell-off drove the stock price down over 40% to its current level of around $119…
Cathie Wood’s ARK Invest Buys for 8
Here's a look at the ARK Invest Buys for August 19, 2021.
How come CRSP earned so much money in Q2? : stocks
$760 M of profits when previously they had no revenue stream. How come? CRISPR Therapeutics AG is a Swiss–American biotechnology company …
Illumina vs. CRISPR: Which Genomics Stock is a Better Choice? By StockNews
Illumina vs. CRISPR: Which Genomics Stock is a Better Choice?
Cathie Wood’s ARK Invest Buys Over 1.3 Million Shares of This Health Information Company – 24
One of Cathie Wood's ARK Invest funds bought over 1.3 shares of Sema4 on August 17.
Cathie Wood’s ARK Invest Buys for 8
Here's a look at the ARK Invest Buys for August 17, 2021.
Cathie Wood’s ARK Invest Buys Over 2.5 Million Shares of Palantir – 24
A few of Cathie Wood's ARK Invest funds bought over 2.5 million shares altogether of Palantir on August 16.
CRISPR Therapeutics : Corporate Presentation
®
Creating transformative gene-based medicines for serious diseases
Corporate Overview | August… | August 16, 2021
Will Moderna’s Interest Boost Gene Editing Stocks?
Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from a single stock, Intellia Therapeutics, which is up by about 3x year-to-date, after the company…
Saturna Capital CORP Buys Microsoft Corp, Alphabet Inc, Mastercard Inc, Sells Bristol-Myers Squibb Company, Xilinx Inc, RPM International Inc
GuruFocus Article or News written by insider and the topic is about:
Discovery Value Fund Buys Roblox Corp, Intellia Therapeutics Inc, Coinbase Global Inc, Sells Coupa Software Inc, Peloton Interactive Inc, Li Auto Inc
GuruFocus Article or News written by insider and the topic is about:
Hershey Trust Co Buys iShares MSCI EAFE Small-Cap ETF, Pinduoduo Inc, Teladoc Health Inc, Sells iShares Russell 2000 ETF, Wayfair Inc, Lemonade Inc
GuruFocus Article or News written by insider and the topic is about:
Crispr Therapeutics Ag (CRSP) CEO Samarth Kulkarni Sold $3.9 million of Shares
GuruFocus Article or News written by insider and the topic is about:
Why CRISPR Therapeutics Stock Fell 25.2% in July
The stock dropped roughly $40 per share over the course of the month.
Cathie Wood’s ARK Invest Doubles Down on Buying This Biotech-Focused SPAC – 24/7 Wall St.
On August 5, one ARK Invest fund bought nearly 2 million shares of Soaring Eagle Acquisition, a biotech-focused special purpose acquisition company. This is adding to the 4 million shares it bought on Thursday.
S&P, NASDAQ Set New Highs While Waiting for Jobs Report
Stocks Analysis by Zacks Investment Research covering: Cross Country Healthcare Inc, Pacific Biosciences of California, Materion Corporation, Editas Medicine Inc. Read Zacks Investment Research's latest article on Investing.com
CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 05, 2021 — CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today… | August 5, 2021
Cathie Wood’s ARK Invest Buys for 8
Here's a look at the ARK Invest buys for August 4, 2021.
Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?
After receiving yet another treatment approval from regulators, Bluebird Bio looks like a bargain.
Better Buy: Vertex vs. CRISPR
Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run.
CRISPR Therapeutics AG (CRSP) Tops Q2 Earnings and Revenue Estimates
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 125.30% and 32.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics : More than 45 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 (Form 8-K)
– More than 45 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021-
… | July 29, 2021
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $119, marking a -0.63% move from the previous day.
Is CRISPR Therapeutics a Millionaire-Maker Stock?
It's already well on its way, but the road ahead will be long.
3 Things About CRISPR Therapeutics That Smart Investors Know
The company is on track to be the first to market with a gene-editing therapy for blood disorders.
Arkk has some new direct competition : investing
The Jacob Forward ETF (JFWD) launched on Wednesday, trading on the NYSE Arca. In an interview, Jacob admits there are plenty of similarities between …
3 Things About Vertex Pharmaceuticals That Smart Investors Know
Can one multibillion-dollar blockbuster breakthrough lead to another?
Traynor Capital Management, Inc. Buys DoorDash Inc, Airbnb Inc, CRISPR Therapeutics AG, Sells MercadoLibre Inc, Atomera Inc, ARK Innovation ETF
GuruFocus Article or News written by insider and the topic is about:
Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending
According to Goldman Sachs, mergers and acquisitions have reached new heights in 2021. Ramin Talaie/Getty Images Goldman Sachs says S&P 50…
Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending
According to Goldman Sachs, mergers and acquisitions have reached new heights in 2021. Ramin Talaie/Getty Images Goldman Sachs says S&P 50…
Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending
According to Goldman Sachs, mergers and acquisitions have reached new heights in 2021. Ramin Talaie/Getty Images Goldman Sachs says S&P 50…
CRISPR Therapeutics AG (CRSP) Stock Moves -0.67%: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $126.25 in the latest trading session, marking a -0.67% move from the prior day.
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.
Apis Capital Deep Value Fund 2Q21 Commentary
Apis Capital Deep Value Fund was up 2.8% net in Q2 2021. During the past quarter, our longs contributed 9.2 percent (gross).
Jim Cramer’s Top Picks to Stand Up to Inflation – 24
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Vera Therapeutics Appoints Sean Grant as Chief Financial Officer
Healthcare and financial services industry veteran brings nearly 15 years of multi-disciplinary financial experience and proven track record in strategic…
Should I Buy WEX Inc (WEX)?
At Insider Monkey, we pore over the filings of nearly 866 top investment firms every quarter, a process we have now completed for the latest reporting…
Is The Middleby Corporation (MIDD) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….